Real-World Impact of Low-Grade Toxicities to Adjuvant Pembrolizumab in Stage III Melanoma
In addition to the impact of grade 3 to 4 toxicities, there is a substantial burden of low-grade toxicity in patients undergoing adjuvant pembrolizumab treatment for stage III melanoma. Clinicians should discuss its potentially significant impact with patients and prepare to support them through these effects.
Authors
- Sharanniyan Ragavan (ORCID: https://orcid.org/0000-0002-0490-1135)
- Olabode Oladipo
- Nasreen Abdul Aziz (ORCID: https://orcid.org/0000-0002-7578-5792)
- Ruth Board (ORCID: https://orcid.org/0000-0002-9259-0823)
- David Burke (ORCID: https://orcid.org/0000-0002-8242-0556)
Institutions
- Belfast Health and Social Care Trust (GB)
- Lancashire Teaching Hospitals NHS Foundation Trust (GB)
- University of Ulster (GB)
- Belfast City Hospital (GB)
- Royal Preston Hospital (GB)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1200/op-24-01013
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00